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Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
Aims: To deﬁne the occurrence of KRAS and BRAF
mutations, microsatellite instability (MSI), and MGMT
and hMLH1 methylation and expression in colorectal
serrated adenocarcinoma.
Methods and results: KRAS codon 12 ⁄ 13 and 59 ⁄ 61
and BRAF V600E mutations, MSI, and MGMT and
hMLH1 methylation and expression in 42 serrated
adenocarcinomas and 17 serrated adenomas were
compared with those in 59 non-serrated colorectal
carcinomas (CRCs) and nine adenomas. KRAS and
BRAF mutations were observed in 45% and 33% of
serrated adenocarcinomas and in 27% and 0% of non-
serrated CRCs (P < 0.001). The KRAS c12G ﬁ A
transition was the predominant type of mutation in
serrated adenocarcinomas. Forty-two per cent of BRAF-
mutated serrated adenocarcinomas showed high-level
MSI (MSI-H) (P = 0.075), 100% showed hMLH1
methylation (P = 0.001) and 90.9% showed MGMT
methylation (P = 0.019). Fifty-six per cent of serrated
adenocarcinomas with microsatellite stability ⁄ low-le-
vel microsatellite instability harboured KRAS muta-
tions. In non-serrated cancers, KRAS mutations were
not associated with MSI status.
Conclusions: A high combined mutation rate (79–
82%) of KRAS and BRAF in serrated adenomas and
adenocarcinomas indicates that mitogen-activated
protein kinase activation is a crucial part of the
serrated pathway. BRAF mutations are speciﬁc for
serrated adenocarcinoma and identify a subset of
serrated adenocarcinomas with gene methylation and
a tendency for MSI-H. A high frequency of KRAS
mutations in serrated adenocarcinomas suggests that
a signiﬁcant proportion of KRAS-mutated CRCs orig-
inate from serrated precursors, thus challenging the
traditional model of Vogelstein.
Keywords: BRAF, colorectal cancer, DNA hypermethylation, hMLH1, KRAS, MGMT, microsatellite instability,
serrated adenocarcinoma
Abbreviations: CIM, CpG island hypermethylation; CRC, colorectal carcinoma; MAPK, mitogen-activated protein
kinase; MSI, microsatellite instability; MSI-H, high-level microsatellite instability; MSI-L, low-level microsatellite
instability; MSS, microsatellite stability; PCR, polymerase chain reaction
Introduction
Colorectal cancer (CRC) is the second most common
cancer type in the Western world.
1 For a long time,
non-serrated adenomas were thought to represent the
only signiﬁcant precursor lesion for CRC.
2 However, it
is now apparent that the development of 15–20% of
sporadic CRCs is not explained by Vogelstein’s ade-
noma–carcinoma model. These cancers often show
concurrent BRAF mutations and DNA CpG island
hypermethylation (CIM), and associate with high-level
DNA microsatellite instability (MSI-H) via methylation
of the DNA mismatch repair gene hMLH.
3,4 It is
generally believed that these cancers originate from
serrated polyps, because this combination of alterations
Address for correspondence: M J Ma ¨kinen, Department of Pathology,
Institute of Diagnostics, University of Oulu, POB 5000FIN-90014,
University of Oulu, Finland. e-mail: markus.makinen@oulu.ﬁ
*These authors contributed equally to this study.
Re-use of this article is permitted in accordance with the Terms and
Conditions set out at http://wileyonlinelibrary.com/onlineopen#
OnlineOpen_Terms
  2011 Blackwell Publishing Limited.
Histopathology 2011, 58, 679–692. DOI: 10.1111/j.1365-2559.2011.03821.xis frequent in serrated polyps (hyperplastic polyps,
sessile serrated adenomas, mixed hyperplastic ⁄ adeno-
matous polyps, also known as admixed polyps, and
traditional serrated adenomas), but absent in sporadic
non-serrated adenomas. The serrated pathway has
emerged as the second most signiﬁcant pathway
leading to CRC. A smaller subset of CRCs, at least
7.5%, can be distinguished by their morphology as
being derived from serrated precursor lesions, even
when such precursor lesions are no longer visible. We
have referred to them as ‘serrated adenocarcinoma’ to
indicate their origin in serrated polyps. Although many
of these cancers retain a serrated pattern of epithelium,
poorly differentiated ones are better characterized by
abundant eosinophilic cytoplasm and a trabecular
growth pattern.
4,5
KRAS mutations have been considered to be the
hallmark mutations of Vogelstein’s adenoma–carci-
noma model. Given the fact that the development of
CRCs from serrated polyps with KRAS mutations has
not yet been described, KRAS-mutated serrated polyps
have been suggested to make a minor contribution to
CRC development.
6,7
KRAS and BAF belong to the intracellular
RAS ⁄ RAF ⁄ MEK ⁄ mitogen-activated protein kinase
(MAPK) cascade, which mediates cellular responses to
growth signals. Activating mutations of KRAS occur in
30–50% of CRCs.
8,9 Most (90%) are found in codons
12 and 13 of exon 1, and about 5% in codons 59 and
61 of exon 2.
10 A single missense mutation of BRAF
(BRAF V600E) accounts for 80% of the mutations in
CRCs.
11,12 Both BRAF and KRAS mutations have been
found in the earliest detectable lesions with a serrated
morphology, i.e. in hyperplastic ⁄ heteroplastic aberrant
crypt foci.
4,13 BRAF mutations have been reported in
19–36% of hyperplastic polyps, in 40–89% of admixed
polyps, in 75–82% of sessile serrated adenomas, and in
20–66% of traditional serrated adenomas.
3,4,14,15
Similarly, KRAS mutations have been reported in
about 18% of aberrant crypt foci, in 4–37% of
hyperplastic polyps, in 60% of admixed polyps, in up
to 80% of traditional serrated adenomas, and in up to
10% of sessile serrated adenomas.
4,16
A recent study based on 11 cases found BRAF
mutations to be frequent and highly speciﬁc for
serrated adenocarcinoma,
17 but the signiﬁcance of
KRAS mutations in serrated adenocarcinoma develop-
ment is not known. Therefore, this study was con-
ducted in order to identify the prevalence of BRAF and
KRAS mutations in serrated adenomas and serrated
adenocarcinomas, and their potential associations with
both the microsatellite instability (MSI) status and the
methylation of hMLH1 and MGMT, which are known
to be altered in serrated polyps and in the sporadic
MSI ⁄ methylator pathway to CRC.
Materials and methods
materials
Altogether, 47 serrated adenocarcinomas were ob-
tained for this study. The histology was conﬁrmed by
two independent pathologists (M.J.M. and T.J.K.) from
the haematoxylin and eosin-stained slides. Samples
were diagnosed as serrated adenocarcinomas when the
cancer tissue was composed of epithelial proliferation
reminiscent of serrated adenoma, i.e. the cytoplasm of
these cells was clear or eosinophilic, and when the
cellular changes were accompanied by a serrated
growth pattern, i.e. cells forming pseudopapillary or
pseudocribriform structures with tufting of the cells
into the lumen without true papillary structures with a
ﬁbrovascular core.
5 CRC specimens with serrated
morphology were screened from the previously de-
scribed, consecutively collected and population-based
Finnish collection of 466 samples.
18 This material
yielded 38 serrated cases, of which 35 were previously
diagnosed as serrated cancers.
5 After careful review,
three cases were reclassiﬁed as serrated adenocarcino-
mas. These cases did not have a residual serrated
adenoma component (see Figure 1B for an example).
The original series of samples was extended to cover
the years 1997–1998, raising the number of samples
in the consecutive series to 552 and the number of
serrated CRCs to 45. Two additional serrated cases
removed between the years 2006 and 2007 were
included. With ﬁve serrated cases of the consecutive
series lacking sufﬁcient sample material, 42 ⁄ 47 ser-
rated CRCs were included in the DNA analyses of the
present study. For the sake of simplicity, we have
referred to all the other adenomas and carcinomas as
‘non-serrated’ in this paper.
A control series of non-serrated adenocarcinomas
(n = 32) was selected from the demographic series of
552 cases to match gender, location, Dukes’ stage and
World Health Organization histological grade. In the
proximal colon, serrated adenocarcinomas represented
such a large proportion that matched controls could
not be obtained for all cases. Therefore, the matched
control group remained smaller than the study group,
and thus a set of 27 unmatched non-serrated adeno-
carcinomas selected from the same series to the study
was added, yielding a total of 59 non-serrated adeno-
carcinomas.
Residual benign, serrated adenoma in contact
with cancer tissue was present in 28 ⁄ 42 serrated
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adenoma tissue was separately collected for the
analyses. In nine cases of serrated adenocarcinoma,
the residual serrated adenoma tissue was available for
the analyses. An additional set of 17 serrated adeno-
mas and nine non-serrated adenomas with a size of
5 mm or more was retrieved from the archives of Oulu
University Hospital Department of Pathology.
dna extraction and msi analysis
DNA extraction and MSI analysis were performed as
described previously.
5,19 Tumour DNA was analysed
with the NIH consensus marker panel, and distinction
of MSI-H from microsatellite stability (MSS) ⁄ low-level
MSI (MSI-L) was made according to the NIH consensus
statement.
20
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Figure 1. Representative histological sections of serrated adenocarcinomas in regard to KRAS or BRAF mutations and microsatellite
instability (MSI) status. A–C, Cases of serrated adenocarcinomas with BRAF V600E mutations. D–F, Serrated adenocarcinomas with KRAS c12
mutations. G–H, Serrated adenoma and adenocarcinoma wild type for BRAF and KRAS, but presenting with high-level MSI (MSI-H). A, A case
of serrated adenocarcinoma of the proximal colon with MSI-H, and harbouring a BRAF V600E mutation. This case is well differentiated
and mucin-producing. The serrated epithelial folding is conspicuous. B, Another case of serrated adenocarcinoma of the proximal colon with
MSI-H, and harbouring a BRAF V600E mutation, initially diagnosed as conventional adenocarcinoma. Serrated epithelial folding is less
conspicuous, but present (arrowheads). C, A case of a serrated adenocarcinoma of the proximal colon with microsatellite stability (MSS),
presenting with BRAF V600E mutation. D, A case of a serrated adenocarcinoma of the proximal colon with MSS, and harbouring a KRAS
mutation. The serrations are apparent. E, A case of serrated adenocarcinoma of the proximal colon with MSS ⁄ low-level MSI, and harbouring
a KRAS mutation. There is abundant clear cytoplasm, preserved polarity and luminal serration. F, A case of serrated adenocarcinoma of the
proximal colon with MSI-H, and harbouring a KRAS mutation. There is a prominent serrated pattern with epithelial tufting towards the lumen.
G, A case of traditional serrated adenoma of the proximal colon. This tumour was wild type for both KRAS and BRAF, and had MSI-H. The
patient was 78 years old. There was no evidence of hereditary non-polyposis colorectal carcinoma. H, A case of serrated adenocarcinoma
adjacent to the traditional serrated adenoma shown in (G). The tumour shows preserved serrations (arrowheads).
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Methylation analyses of the promoter sequences of the
hMLH1 and MGMT genes were performed using the
methylation-speciﬁc polymerase chain reaction (PCR)
21
based on bisulphite pretreatment of DNA. The primer
pairs used for the methylated and unmethylated tem-
plates of hMLH1 were TTTTTTAGGAGTGAAGGAGGT-
TACG (forward) and GCCACTACGAAACTAAACACG-
AA(reverse),andTTTTTAGGAGTGAAGGAGGTTATGG
(forward) and AAACACCACTACAAAACTAAACACA-
AA (reverse), respectively. The primer pairs used for the
methylated and unmethylated templates of MGMT were
TTTCGACGTTCGTAGGTTTTCGC (forward) and GCAC-
TCTTCCGAAAACGAAACG (reverse),
22 and TTTGTGT-
TTTGATGTTTGTAGGTTTTTGT (forward) and AACTC-
CACACTCTTCCAAAAACAAAACA (reverse), respec-
tively. Bisulphite-treated genomic DNA (100 ng) was
used as a template in the PCR. The 2· JumpStart RED
Taq ReadyMix (Sigma-Aldrich, St Louis, MO, USA) was
used according to the manufacturer’s instructions.
Commercial methylated DNA (CpGENOME Methylated
DNA) and unmethylated DNA (CpGENOME Unmethy-
lated DNA) were included in all the analyses as internal
controls (Chemicon International, Temecula, CA, USA).
The PCR products were visualized with UV illumination
on a 2.5% agarose gel. The results of the methylation
analyses of the hMLH1 and MGMT genes were com-
pared with the intensity of the immunoreaction of the
corresponding proteins.
5
mutation analysis
Mutation analyses of BRAF V600E and KRAS were
performed by direct sequencing with PCR-ampliﬁed
template DNA (25 ng), using a dynazyme DNA poly-
merase kit (Finnzymes Oy, Espoo, Finland). The primers
used in the analysis were AAACTCTTCATAATGCTTG-
CTCTG (forward) and GGCCAAAAATTTAATCAGTG-
GA (reverse) for BRAF V600E, TGGTGGAGTATTT-
GATAGTGTA (forward) and ATGGTCCTGCACCAGTA-
ATA (reverse) for KRAS c12 ⁄ 13, and TGAAGTAAAA-
GGTGCACTGTAATA (forward) and TAAACCCACC-
TATAATGGTGAA (reverse) for KRAS c59 ⁄ 61. PCR
conditions are available on request. The ampliﬁcations
were performed with a PTC-200 thermal cycler (MJ
Research, Waltham, MA, USA). The PCR products
were enzymatically puriﬁed with EXOSAPit (USB,
Cleveland, OH, USA) according to the manufacturer’s
instructions. Sequencing of the product was performed
in both directions on the ABI 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA), with the
forward and reverse primers. The data obtained were
analysed with CHROMAS 1.6 sequencing analysis
software (Technelysium Pty, Halensvale, Australia).
All mutations were reconﬁrmed by independent PCR
reactions and sequencing.
immunohistochemistry
MLH1 and MSH2 analyses were carried out as
described previously.
5 Brieﬂy, mouse monoclonal anti-
bodies for MLH1 and MSH2 (BD-PharMingen, San
Diego, CA, USA) were applied at a dilution of 1:25
(MLH1) or 1:50 (MSH2) for 1 h at room temperature.
The reaction in the tumour area was considered to be
negative if there was no staining in any of the tumour
cell nuclei. For MGMT analysis, tissue sections were
pretreated in 0.01 m citrate (pH 6.0) buffer in a
microwave oven at 800 W for 2 min and at 300 W
Table 1. The success rates of DNA analyses
Serrated
CRCs
Matched
non-serrated
CRCs
All
non-serrated
CRCs
Serrated
adenomas
Serrated adenomas
adjacent to cancer
Non-serrated
adenomas
BRAF V600E 42 ⁄ 42 31 ⁄ 32 49 ⁄ 59 17 ⁄ 17 9 ⁄ 99 ⁄ 9
KRAS c12 ⁄ 13 42 ⁄ 42 32 ⁄ 32 45 ⁄ 59 17 ⁄ 17 9 ⁄ 99 ⁄ 9
KRAS c59 ⁄ 61 40 ⁄ 42 31 ⁄ 32 56 ⁄ 59 17 ⁄ 17 8 ⁄ 99 ⁄ 9
MSI analyses 37 ⁄ 42 30 ⁄ 32 56 ⁄ 59 11 ⁄ 17 2 ⁄ 94 ⁄ 9
Methylation analyses
hMLH1 27 ⁄ 42 29 ⁄ 32 51 ⁄ 59 – – –
MGMT 29 ⁄ 42 29 ⁄ 32 53 ⁄ 59 – – –
CRC, Colorectal carcinoma.
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a dilution of 1:300 for 1 h at room temperature. A
Dako EnVision kit (Dako, Copenhagen, Denmark) was
used in the detection of the bound antibodies, with
3,3¢-diaminobenzidine as a chromogen. The reaction in
the tumour area was considered to be negative if less
than 10% of the tumour cell nuclei stained positive.
statistical analysis
Tests were performed with statistical software (SPSS
16.1; SPSS, Chicago, IL, USA). The chi-square-test or
Fisher’s exact test were used unless otherwise stated. A
P-value of <0.05 was considered to be statistically
signiﬁcant.
ethical aspects
The protocol (58 ⁄ 2002) was approved by the Ethical
Committee of Oulu University Hospital.
Results
The success rates of each DNA analyses are shown in
Table 1. Clinicopathological features of the study
material are presented in Tables 2 and 3, and exam-
ples of serrated adenocarcinomas in relation to KRAS
and BRAF mutations and MSI status are illustrated in
Figure 1. BRAF and KRAS mutations did not coexist.
The prevalence and distribution patterns of BRAF
V600E, KRAS c12 ⁄ 13 and KRAS c59 ⁄ 61 mutations
Table 2. The clinical and pathological features of serrated and non-serrated adenocarcinomas
Serrated adenocarcinomas
(n = 42)
Non-serrated adenocarcinomas
(n = 59) P-value (v
2-test)
Mean age in years (range) 67.5 (43–85) 68.5 (38–88)
Gender, N (%)
Male 17 (40.5) 23 (39.0) 0.880
Female 25 (59.5) 36 (61.0)
Location, N (%)
Proximal colon 24 (57.1) 20 (33.9) 0.050
Distal colon 6 (14.3) 9 (15.3)
Rectum ⁄ rectosigmoid colon 12 (28.6) 30 (50.8)
Grade, N (%)
I 14 (33.3) 11 (18.6) 0.085
II 20 (47.6) 41 (69.5)
III 8 (19.0) 7 (11.9)
Dukes’ stage, N (%)
A 6 (14.3) 13 (22.0) 0.699
B 20 (47.6) 23 (39.0)
C 10 (23.8) 16 (27.1)
D 6 (14.3) 7 (11.9)
Mucinous, N (%)
No 26 (61.9) 54 (91.5) <0.001
Yes 16 (38.1) 5 (8.5)
MSI
MSI-H 7 (18.9) 4 (7.1) 0.164
MSS ⁄ MSI-L 30 (81.1) 52 (92.9)
MSI, Microsatellite instability; MSI-H, high-level MSI; MSI-L, low-level MSI.
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frequent (33.3%; 14 ⁄ 42) and speciﬁc to serrated
adenocarcinomas. After a careful histopathological
re-evaluation of the cases, three BRAF-mutated cases,
originally placed in the control group, were reclassiﬁed
as serrated adenocarcinomas because the serrated
morphology was preserved in the tumour. KRAS
mutations were more frequent in serrated adenocar-
cinomas (45.2%) than in non-serrated adenocarcino-
mas (27.1%; P = 0.002). The higher frequency of
KRAS mutations was clearly more evident (although
not statistically signiﬁcant) in cancers with a residual
serrated adenoma (57.1%, 16 ⁄ 28), being observed
twice as often as BRAF mutations (28.6%, 8 ⁄ 28). The
combined prevalence of BRAF and KRAS mutations
(78.6%) in serrated adenocarcinomas was higher than
in non-serrated adenocarcinomas (27.1%; P < 0.001;
Table 4), and the combined prevalence of BRAF and
KRAS mutations in serrated adenocarcinomas with a
residual serrated adenoma component reached 85.7%
(24 ⁄ 28). In adenomas, BRAF mutations were speciﬁc
to serrated adenomas, as none of the non-serrated
adenomas showed a BRAF mutation (P = 0.058).
Only one non-serrated adenoma carried a KRAS
mutation. Either BRAF or KRAS mutation was
observed in 82.4% of serrated adenomas (P < 0.001;
Table 4).
Among non-serrated adenocarcinomas, KRAS
c12 ⁄ 13 and c59 mutations were found in 16 cases
(Table 4). The mutation pattern of KRAS c12 ⁄ 13 and
c59 ⁄ 61 is shown in Table 5. The c12 G ﬁ A transi-
tions were found in 52.6% (10 ⁄ 19) of KRAS-mutated
serrated adenocarcinomas and in 12.5% (2 ⁄ 16;
P = 0.047) of KRAS-mutated non-serrated cancers.
This transition showed a distinct association with
serrated adenocarcinomas, being present in 24% of
cases (10 ⁄ 42), but in only 3.4% of non-serrated
carcinomas (2 ⁄ 59; P = 0.001; Fisher’s exact test).
The MSI analyses in carcinoma material were
successful in 93 cases (Table 1). Concurrent data from
the MSI analyses and the KRAS ⁄ BRAF mutation
analyses were obtained in 74 carcinoma cases (Ta-
ble 6). Five BRAF mutations and one KRAS c61
mutation were observed among 11 MSI-H cancers
when unmatched cases were included (P = 0.007)
(Table 6). Serrated adenocarcinomas presenting with
MSI-H were unlikely to be hereditary non-polyposis
CRC cases. They occurred in old patients (Table 7) and
presented with an adjacent sessile serrated adenoma
(cases 1 and 5 in Table 7) or traditional serrated
adenoma (cases 2, 3 and 6 in Table 7). Sixty-three
MSS ⁄ MSI-L cancers showed an almost equal distribu-
tion of the wild-type cancers and KRAS-mutated
cancers (P = 0.007; Table 6).
Seven of 34 serrated adenocarcinomas showed MSI-
H (20.6%), and ﬁve of them (71.4%) had a concurrent
BRAF mutation (P = 0.075; Table 6). One MSI-H case
was wild type for both BRAF and KRAS, and another
Table 3. The clinical and
pathological features of
serrated and non-serrated
adenomas
Serrated
adenomas
(n = 26)*
Non-serrated
adenomas
(n =9 )
P-value
(v
2-test)
Mean age in years (range) 64.1 (36–84)* 74.1 (60–83)
Gender, N (%)
Male 13 (50.0) 8 (90) 0.040
Female 13 (50.0) 1 (10)
Location, N (%)
Proximal colon 6 (20) 0 (0) 0.396
Distal colon 4 (5) 2 (20)
Rectum ⁄ rectosigmoid colon 16 (75) 7 (80)
Dysplasia, N (%)
Mild 6 (35) 3 (40) 0.024
Moderate 8 (25) 6 (60)
Severe 12 (40) 0 (0)
*All serrated adenomas, including adenomas adjacent to cancer (n = 9).
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mutations in serrated adenocarcinomas were never
accompanied by MSI-H, in contrast to 15 ⁄ 27 (55.6%)
of MSS ⁄ MSI-L cases harbouring a KRAS mutation
(P = 0.075). In non-serrated adenocarcinomas, MSI-H
and KRAS mutations did not co-occur (P = 0.278).
Analyses with the matched controls yielded similar
results (not shown).
Promoter methylation analysis was successful in
78 ⁄ 101 cases for hMLH1 and in 82 ⁄ 101 cases for
MGMT (Table 1). The relationships between BRAF and
KRAS mutations and hMLH1 and MGMT methylation
Table 4. The prevalence and distribution of BRAF V600E and KRAS (codons 12 ⁄ 13 and 59 ⁄ 61) mutations according to the
type of neoplasm
BRAFV 600E KRAS (all) KRAS c12 ⁄ 13 KRAS c59 ⁄ 61
Either BRAF
or KRAS
Serrated adenocarcinomas (n = 42)
No adjacent adenoma component (n = 14)
With mutation ⁄ all 6 ⁄ 14 3 ⁄ 14 2 ⁄ 14 1 ⁄ 14 9 ⁄ 14
% 42.9 21.4 14.3 7.1 64.3
With adjacent serrated adenoma (n = 28)
With mutation ⁄ all 8 ⁄ 28 16 ⁄ 28 15 ⁄ 28 1 ⁄ 28 24 ⁄ 28
% 28.6 57.1 53.6 3.6 85.7
All (n = 42)
With mutation ⁄ all 14 ⁄ 42 19 ⁄ 42 17 ⁄ 42 2 ⁄ 42 33 ⁄ 42
% 33.3 45.2 40.5 4.8 78.6
Matched non-serrated carcinomas (n = 32)
With mutation ⁄ all 0 ⁄ 32 13 ⁄ 32 12 ⁄ 32 1 ⁄ 32 13 ⁄ 32
% 0 40.6 37.5 3.1 40.6
P <0.001 0.894 1.00 0.842 <0.001
All non-serrated carcinomas (n = 59)
With mutation ⁄ all 0 ⁄ 59 16 ⁄ 59 15 ⁄ 59 1 ⁄ 59 16 ⁄ 59
% 0 27.1 25.4 1.7 27.1
P <0.001 0.002 0.002 0.848 <0.001
Serrated adenomas (n = 17)
With mutation ⁄ all 7 ⁄ 17 7 ⁄ 17 6 ⁄ 17 1 ⁄ 17 14 ⁄ 17
% 41.2 41.2 35.3 5.9 82.4
Non-serrated adenomas (n = 9)
With mutation ⁄ all 0 ⁄ 91 ⁄ 91 ⁄ 90 ⁄ 91 ⁄ 9
% 0 11.1 11.1 0 11.1
P 0.058 0.243 0.453 1 <0.001
Serrated adenomas adjacent to cancer (n = 9)
With mutation ⁄ all 2 ⁄ 94 ⁄ 93 ⁄ 91 ⁄ 96 ⁄ 9
% 22.2 44.4 33.3 11.1 66.7
P 0.068 0.353 0.6 0.436 0.001
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were tightly associated with hMLH1 and MGMT
methylation, whereas KRAS mutations had a negative
correlation with hMLH1 and MGMT methylation
(Table 8). The loss of MGMT expression in immuno-
histochemistry was associated with the corresponding
methylation of the MGMT gene (P < 0.0001; Table 9).
In MSS cancers, the presence of hMLH1 and MGMT
methylation did not correspond to the loss of immu-
nohistochemical expression (not shown), suggesting
incomplete methylation of hMLH1.
Our ﬁndings ﬁt relatively well with the molecular
classiﬁcation of CRC proposed by Jass
6 (Table 10). We
were able to show that Jass groups 1 and 2 deﬁnitely
represent serrated adenocarcinomas, but KRAS-mu-
tated cases belonging to Jass group 3 were composed of
serrated and non-serrated cancers. Most Jass group 4
tumours could be classiﬁed as non-serrated, and most
cases in Jass group 5 were probably Lynch syndrome
cases, except for one case presenting with a typical
serrated growth pattern and residual serrated adenoma
(illustrated in Figure 1G,H).
Discussion
This is the ﬁrst study to show that KRAS mutations are
frequent (45%) in serrated adenocarcinomas, and that
the MAPK activation resulting from either KRAS or
BRAF mutations is very common (79%) in serrated
adenocarcinomas. Earlier studies have claimed that
BRAF predominates over KRAS in biological signiﬁ-
cance in the serrated pathway,
17,23 because: (i) BRAF
mutations are speciﬁc to serrated polyps and serrated
adenocarcinoma; (ii) malignant serrated endpoints
presenting with KRAS mutations have not been
reported until now; and (iii) there has been no previous
evidence that KRAS-mutated CRCs emerge from two
separate molecular pathways.
Sporadic MSI-H cancers have been attributed to the
serrated pathway.
5,14,17,24,25 In our study, MSI-H was
seen in only 20.6% of serrated adenocarcinomas. A
distinct association of BRAF mutations with MSI-H and
the methylation of hMLH1 and MGMT was observed
among serrated cases, thus corroborating the idea that
BRAF-mutated CRCs (Jass groups 1 and 2) represent
serrated adenocarcinomas with high accuracy,
6,14,26
but the relatively low frequency of MSI-H cancers
among serrated adenocarcinomas indicates that spo-
radic MSI-H colorectal cancers can be attributed only
to a subset of serrated adenocarcinomas.
4,5,14
The serrated adenocarcinoma cases presenting with
a residual adenoma component undoubtedly showed
KRAS mutations (57.1%) to be twice as frequent as
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mas. Either KRAS or BRAF mutation was observed in
85.7% of these cases, and in 82.4% of the serrated
adenomas. These numbers suggest that MAPK activa-
tion is central for the serrated adenocarcinoma path-
way, and that many CRCs with KRAS mutations,
MSS ⁄ MSI-L and less frequent DNA hypermethylation
originate from serrated polyps.
KRAS mutations have generally been considered to
be characteristic of Vogelstein’s adenoma–carcinoma
model, and the integration of KRAS mutation in the
model was justiﬁed by the high frequency of KRAS
mutations in CRCs. Recent, well-conducted studies
based on extensive case series – carried out after the
recognition of serrated adenomas – have repeatedly
found that KRAS mutations are rare in tubular
Table 6. The prevalences of BRAF V600E and KRAS mutations in serrated and non-serrated adenomas and adenocarcinomas
with high-level microsatellite instability (MSI-H) and microsatellite stability (MSS) ⁄ low-level microsatellite instability (MSI-L)
Mutation All, N
MSS ⁄ MSI-L,
n (%)
MSI-H,
n (%)
P-value
(Fisher’s
exact test)
All CRC BRAF V600E mutation 12 7 (58.3) 5 (41.7) 0.007
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 31 30 (96.8) 1 (3.2)
Wild type 31 26 (83.9) 5 (16.1)
Serrated CRC with their
matched controls
BRAF V600E mutation 12 7 (58.3) 5 (41.7) 0.008
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 29 28 (96.5) 1 (3.5)
Wild type 23 18 (78.3) 5 (21.7)
Serrated CRC BRAF V600E mutation 12 7 (58.3) 5 (41.7) 0.075
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 16 15 (93.8) 1 (6.2)
Wild type 6 5 (83.3) 1 (16.7)
Non-serrated CRC BRAF V600E mutation 0 0 (0) 0 (0) 0.278
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 15 15 (100) 0 (0)
Wild type 25 21 (84) 4 (16.0)
Matched non-serrated
CRCs
BRAF V600E mutation 0 0 (0) 0 (0) 0.113
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 13 13 (100) 0 (0)
Wild type 17 13 (76.5) 4 (23.5)
All adenomas BRAF V600E mutation 4 4 (100) 0 (0) 0.588
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 7 7 (100) 0 (0)
Wild type 6 5 (83.3) 1 (16.7)
Serrated adenomas BRAF V600E mutation 4 4 (100) 0 (0) NA
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 7 7 (100) 0 (0)
Wild type 2 2 (100) 0 (0)
Non-serrated adenomas BRAF V600E mutation 0 0 (0) 0 (0) NA
KRAS c12 ⁄ 13 or c59 ⁄ 61 mutation 0 0 (0) 0 (0)
Wild type 4 3 (75) 1 (25.0)
CRC, Colorectal carcinoma; NA, not applicable.
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non-serrated adenomas.
27,28 Barry et al.
28 documented
a 3% frequency of KRAS mutations in a prospective
study of 303 adenomas, most mutations being
observed in sessile and tubulovillous adenomas. Only
two of 259 tubular adenomas (0.8%) harboured a
KRAS mutation. Maltzman et al.
27reported a 10.6%
frequency for KRAS mutations in tubular adenomas.
The high frequency of KRAS mutations in serrated
adenomas and serrated adenocarcinomas observed in
the present study explains, in part, why KRAS muta-
tions are less frequent in non-serrated adenomas but
occur in abount 40% of CRCs.
The high frequency of KRAS mutations in serrated
adenocarcinomas further strengthens the importance of
the colorectal serrated pathway. The estimated 15–20%
frequency of serrated adenocarcinomas is based on the
frequency of sporadic BRAF-mutated, CIM-positive
CRCs.
4 If KRAS-mutated serrated adenocarcinomas
were taken into account, the proportion of the serrated
pathway could reach 30% of all CRCs: KRAS mutations
are more frequent in serrated polyps than in non-
serrated adenomas, being observed in up to 37% of
hyperplastic polyps, in up to 60% of admixed polyps,
and in up to 80% of traditional serrated adenomas.
4,16
The given frequencies of 30–50% for KRAS mutations
for all colorectal cancers and 45% for serrated adeno-
carcinomas allow an assumption that 15–30% of
KRAS-mutated CRCs may evolve from serrated adeno-
mas, if we consider that the serrated pathway represents
15–20% of colorectal cancers.
4 A similar conclusion
can be drawn on the basis of polyp demographics. If
traditional serrated adenomas represent 3% and non-
serrated adenomas 85% of all polyps, then the 80%
KRAS mutation rate in traditional serrated adenomas
and the 3% mutation rate in non-serrated adenomas
would yield KRAS-mutated polyps in roughly equal
numbers (2.4% and 2.6% of all polyps, respectively).
It must be emphasized that serrated adenocarcinoma
has not been considered as an entity in any of the
Table 8. Mutation status of BRAF and KRAS according to the promoter methylation status of hMLH1 and MGMT in serrated
and non-serrated cancers
hMLH1 methylation MGMT methylation
All, N
Yes No
P-value All, N
Yes No
P-value n (%) n (%) n (%) n (%)
Serrated adenocarcinoma
BRAF V600E 10 10 (100) 0 (0.0) 0.001 11 10 (90.9) 1 (9.1) 0.019
Wild-type BRAF 17 6 (35.3) 11 (64.7 18 8 (44.4) 10 (55.6)
KRAS c12 ⁄ 13 or c59 ⁄ 61 13 5 (38.5) 8 (61.5) 0.034 14 5 (35.5) 9 (64.3) 0.005
Wild-type KRAS (all) 14 11 (78.6) 3 (21.4) 15 13 (86.7) 2 (13.3)
All non-serrated cancers
BRAF V600E 0 0 0 NA 0 0 0 NA
Wild-type BRAF 43 10 (23.3) 33 (76.7) 43 18 (41.9) 25 (58.1)
KRAS c12 ⁄ 13 or c59 ⁄ 61 16 1 (6.3) 15 (93.8) 0.108 16 3 (18.8) 13 (81.3) 0.084
Wild-type KRAS (all) 25 7 (28.0) 18 (72.0) 25 13 (52.0) 12 (48.0)
Matched non-serrated cancers
BRAF V600E 0 0 0 NA 0 0 0 NA
Wild-type BRAF 28 5 (17.9) 23 (82.1) 28 14 (25.0) 14 (25.0)
KRAS c12 ⁄ 13 or c59 ⁄ 61 13 1 (7.7) 12 (92.3) 0.343 15 3 (23.1) 10 (76.9) 0.014
Wild-type KRAS (all) 16 4 (25.0) 12 (75.0) 16 11 (68.8) 5 (31.2)
NA, Not applicable.
KRAS and BRAF in serrated adenocarcinoma 689
  2011 Blackwell Publishing Ltd, Histopathology, 58, 679–692.T
a
b
l
e
9
.
T
h
e
c
o
r
r
e
l
a
t
i
o
n
o
f
M
G
M
T
⁄
h
M
L
H
1
p
r
o
m
o
t
e
r
m
e
t
h
y
l
a
t
i
o
n
w
i
t
h
t
h
e
i
m
m
u
n
o
r
e
a
c
t
i
o
n
o
f
t
h
e
c
o
r
r
e
s
p
o
n
d
i
n
g
p
r
o
t
e
i
n
s
i
n
a
l
l
c
a
n
c
e
r
s
,
s
e
r
r
a
t
e
d
c
a
n
c
e
r
s
a
n
d
t
h
e
i
r
m
a
t
c
h
e
d
c
o
n
t
r
o
l
s
P
r
o
m
o
t
e
r
m
e
t
h
y
l
a
t
i
o
n
o
f
M
G
M
T
⁄
h
M
L
H
1
A
l
l
,
N
M
G
M
T
e
x
p
r
e
s
s
i
o
n
*
P
-
v
a
l
u
e
(
F
i
s
h
e
r
’
s
e
x
a
c
t
t
e
s
t
)
A
l
l
,
N
h
M
L
H
1
e
x
p
r
e
s
s
i
o
n
P
-
v
a
l
u
e
(
F
i
s
h
e
r
’
s
e
x
a
c
t
t
e
s
t
)
P
o
s
i
t
i
v
e
N
e
g
a
t
i
v
e
P
o
s
i
t
i
v
e
N
e
g
a
t
i
v
e
A
l
l
c
a
s
e
s
U
n
m
e
t
h
y
l
a
t
e
d
4
5
4
5
0
<
0
.
0
0
0
1
5
2
4
8
4
0
.
0
8
6
U
n
m
e
t
h
y
l
a
t
e
d
a
n
d
m
e
t
h
y
l
a
t
e
d
2
7
2
1
6
2
5
2
1
4
M
e
t
h
y
l
a
t
e
d
1
1
5
6
5
3
2
S
e
r
r
a
t
e
d
C
R
C
U
n
m
e
t
h
y
l
a
t
e
d
1
3
1
3
0
0
.
0
4
1
1
3
1
2
1
0
.
1
8
6
U
n
m
e
t
h
y
l
a
t
e
d
a
n
d
m
e
t
h
y
l
a
t
e
d
1
7
1
3
4
1
4
1
1
3
M
e
t
h
y
l
a
t
e
d
4
2
2
4
2
2
M
a
t
c
h
e
d
c
o
n
t
r
o
l
s
U
n
m
e
t
h
y
l
a
t
e
d
1
6
1
6
0
0
.
0
1
3
2
4
2
1
3
0
.
5
5
3
U
n
m
e
t
h
y
l
a
t
e
d
a
n
d
m
e
t
h
y
l
a
t
e
d
6
4
2
4
3
1
M
e
t
h
y
l
a
t
e
d
6
3
3
1
1
0
F
o
r
*
M
G
M
T
i
m
m
u
n
o
r
e
a
c
t
i
o
n
,
t
u
m
o
u
r
t
i
s
s
u
e
p
r
e
s
e
n
t
i
n
g
o
v
e
r
1
0
%
o
f
p
o
s
i
t
i
v
e
c
e
l
l
s
w
a
s
c
o
n
s
i
d
e
r
e
d
t
o
b
e
p
o
s
i
t
i
v
e
.
C
R
C
,
C
o
l
o
r
e
c
t
a
l
c
a
r
c
i
n
o
m
a
.
690 K Stefanius et al.
  2011 Blackwell Publishing Ltd, Histopathology, 58, 679–692.previous studies on the frequency and pathogenesis of
KRAS-mutated CRCs.
29–31 This should be kept in mind
when interpreting previous data on the KRAS mutation
rate in CRCs. The Vogelstein adenoma–carcinoma
model, published in 1990, was constructed ahead of
the description of serrated adenomas in the same year.
Therefore, it is likely that the Vogelstein model was
originally contaminated by observations on (tradi-
tional) serrated adenomas bearing KRAS mutations
misclassiﬁed as non-serrated adenomas.
The most frequent KRAS mutation in codons 12 ⁄ 13
arec122G ﬁ A(31–38%),c122G ﬁ T(21–31%),c13
2G ﬁ A(13–21%),andc121G ﬁ T(7–10%).
29–31The
relative proportions of speciﬁc types of KRAS mutations
that we identiﬁed were similar to those previously
described(Table 5).However,thec12 G ﬁ Atransition
was almost completely speciﬁc to serrated adenocarci-
nomas, being present in 24% (10 ⁄ 42) of the cases,
whereas in non-serrated carcinomas it was present in
only 3% (2 ⁄ 59) of cases (P = 0.001). Therefore, it is
likely that many CRCs with the KRAS c12 G ﬁ A
transversion represent serrated adenocarcinomas.
Besides providing a potential genetic marker for the
serrated adenocarcinomas, the speciﬁcity of the
c12 G ﬁ A transition may indicate the occurrence of
speciﬁc aetiological factors, such as endogenous envi-
ronmental or endogenous alkylating agents.
22,32 The
speciﬁcity of G ﬁ A transitions to serrated adenocarci-
nomasjustiﬁestheanalysisofspeciﬁcenvironmentalrisk
factors, such as smoking, as possible causative agents.
In conclusion, the cumulative 79–82% frequency
of BRAF and KRAS mutations in serrated adenocarci-
noma and its precursors observed in our study under-
lines the importance of MAPK pathway activation in
the serrated pathway, and suggests that these muta-
tions are the driver mutations in the serrated pathway.
The co-occurrence of BRAF mutations, CIM and MSI-H
represents an easily identiﬁable subset of serrated
adenocarcinoma, and BRAF mutation analysis can
be utilized to detect these cases. However, the high
frequency of KRAS mutations, particularly the
c12 G ﬁ A transition, in serrated neoplasms empha-
sizes that KRAS mutation is an even more important
alteration in the serrated pathway. Many KRAS-
mutated CRCs originate from serrated polyps, and
complete removal and follow-up of serrated adenomas
with KRAS mutations is therefore essential to reduce
the total CRC burden. The high frequency of KRAS
mutations in serrated adenocarcinomas also indicates
that most serrated adenocarcinomas are natively
insensitive to epidermal growth factor receptor-block-
ing therapies, which are increasingly being used to
treat metastatic colorectal cancer.
33,34
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